. . . "0"^^ . . . . . . "\u017Delezo hraje kl\u00ED\u010Dovou roli p\u0159i tvorb\u011B kysl\u00EDkov\u00FDch radik\u00E1l\u016F pova\u017Eovan\u00FDch za rozhoduj\u00EDc\u00ED faktor p\u0159i \u0159ad\u011B patologick\u00FDch stav\u016F v\u010Detn\u011B antracyklinov\u00E9 kardiomyopatie. Mezi nov\u00E9 velmi \u00FA\u010Dinn\u00E9 ligandy \u017Eeleza pat\u0159\u00ED orto-deriv\u00E1ty pyridoxal benzoyl hydrazonu (PBH) aderiv\u00E1ty pyridoxal isonicotinoyl hydrazonu, vyvinut\u00E9 Po\u0148kou. Jedn\u00E1 se o lipofiln\u00ED, intracelul\u00E1rn\u011B prostupuj\u00EDc\u00ED l\u00E1tky s vysokou \u017Eelezo chelatuj\u00EDc\u00ED aktivitou, v\u00FDraznou schopnost\u00ED mobilizace intracelul\u00E1rn\u00EDho \u017Eeleza z bu\u0148ky a s n\u00EDzkou toxicitou. Vzhledem kjejich schopnosti v\u00FDrazn\u011B omezit tvorbu hydroxylov\u00FDch radik\u00E1l\u016F je racion\u00E1ln\u00ED p\u0159edpoklad jejich u\u017Eit\u00ED p\u0159i l\u00E9\u010Db\u011B po\u0161kozen\u00ED tk\u00E1n\u00ED t\u011Bmito radik\u00E1ly. Z hlediska \u0159ady mo\u017En\u00FDch indikac\u00ED t\u011Bchto l\u00E1tek jsou poznatky o jejich vlivu na kardiovaskul\u00E1rn\u00ED syst\u00E9m a nabiotransforma\u010Dn\u00ED mechanismy esenci\u00E1ln\u00ED. C\u00EDlem projektu je: - studium vlivu orto-deriv\u00E1t\u016F pyridoxal benzoyl hydrazonu na biotransforma\u010Dn\u00ED mechanismy in vivo a in vitro v\u010Detn\u011B mezidruhov\u00E9ho srovn\u00E1n\u00ED u experiment\u00E1ln\u00EDch zv\u00ED\u0159at, - studium jejich" . "2009-01-15+01:00"^^ . . . . "Mezi nov\u00E9 \u00FA\u010Dinn\u00E9 aroylhydrazonov\u00E9 chel\u00E1tory \u017Eeleza pat\u0159\u00ED salicylaldehyd isonikotinoyl hydrazon (SIH) a pyridoxal 2-chlorobenzoyl hydrazon (o-108). Chel\u00E1tory byly studov\u00E1ny z\u00A0hlediska: (1) optimalizace jejich farmaceutick\u00E9 formulace pro pod\u00E1n\u00ED in vivo, (2"@cs . . "17"^^ . . "17"^^ . . . "Cardiovascular, Potentially Cardioprotective and Biotransformational Effects of New Iron Chelating Agents."@en . . "GA305/03/1511" . "http://www.isvav.cz/projectDetail.do?rowId=GA305/03/1511"^^ . "Salicylaldehyde isonicotinoyl hydrazone (SIH) and pyridoxal 2-chlorobenzoyl hydrazone (o-108) rank among new effective aroylhydrazone iron chelators. Chelators were studied from the standpoint of: (1) the optimisation of their pharmaceutical formulation"@en . "Kardiovaskul\u00E1rn\u00ED, potenci\u00E1ln\u011B kardioprotektivn\u00ED a biotransforma\u010Dn\u00ED \u00FA\u010Dinky nov\u00FDch l\u00E1tek chelatuj\u00EDc\u00EDch \u017Eelezo" . . . "1"^^ . . "1"^^ . "Neuvedeno."@en . . "Iron plays a key role in the in vivo formation of oxyradicals, which are considered to be the main factor in the aetiology of many pathologies including anthracycline cardiomyopathy. Ortho-halogenated analogs of pyridoxal benzoyl hydrazone (PBH) andpyridoxal isonicotinoyl hydrazone (developed by Ponka) belong to new effective Fe-chelating agents. These lipophilic substances cross biological membranes, posses high Fe chelating efficacy, relatively low toxicity, and are very effective in mobilizingcellular Fe. As these substances can significantly inhibit iron-induced generation of oxyradicals, their possible use in the treatment of free radical-caused tissue damage is well founded. From the viewpoint of a number of therapeutic indications of thedrugs, the knowledge of their influence on the cardiovascular system and biotransformation is essential. The project aims to - investigate the effect of ortho-halogenated analogs of PBH on the mechanisms of biotransformation in vivo and in vitro"@en . .